Point of Care Nano-Technology (PCNT) 10-K 29 Oct 24 2023 FY Annual report Financial data

Cover

Cover - USD ($)	12 Months Ended
	Jul. 31, 2023	Oct. 29, 2024	Jan. 31, 2023
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Annual Report	true
Document Transition Report	false
Document Period End Date	Jul. 31, 2023
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2023
Current Fiscal Year End Date	--07-31
Entity File Number	000-56356
Entity Registrant Name	POINT OF CARE NANO-TECHNOLOGY INC.
Entity Central Index Key	0001504239
Entity Tax Identification Number	27-2830681
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	109 Ambersweet Way
Entity Address, City or Town	Davenport
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	33897
City Area Code	(732)
Local Phone Number	723-7395
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Public Float			$ 41,960
Entity Common Stock, Shares Outstanding		72,690,621
Auditor Name	Fruci & Associates II, PLLC
Auditor Firm ID	5525
Auditor Location	Spokane, Washington

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($)	Jul. 31, 2023	Jul. 31, 2022
Current Assets
Cash	$ 498	$ 3,198
Prepaid Expenses	5,280	2,917
Current Assets	5,778	6,115
Intangible Asset - License (Note 7)	118,865	123,466
Total Assets	124,643	129,581
Current Liabilities
Accounts Payable and Accrued Expenses	141,414	88,335
Total Liabilities	141,414	88,335
Commitments and Contingencies
Stockholders’ Deficit
Preferred Stock, par value $0.0001, (Note 5) 10,000,000 shares authorized; 1,000 shares issued and outstanding	1	1
Common Stock, par value $0.0001, (Note 5) 100,000,000 shares authorized; 420,621 shares issued and outstanding (940,621 in 2022)	42	94
Unissued Common Stock	750,000	750,000
Share Subscriptions Received (Note 5)	20,000
Treasury Stock - 520,000 shares		(52)
Additional Paid-In Capital	120,192,085	120,192,085
Accumulated Deficit	(120,978,899)	(120,900,882)
Total Stockholders’ Deficit	(16,771)	41,246
Total Liabilities and Stockholders’ Deficit	$ 124,643	$ 129,581

CONSOLIDATED BALANCE SHEETS (Pa

CONSOLIDATED BALANCE SHEETS (Parenthetical) - $ / shares	Jul. 31, 2023	Jul. 31, 2022
Statement of Financial Position [Abstract]
Preferred Stock, Par Value	$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Issued	1,000	1,000
Preferred Stock, Shares Outstanding	1,000	1,000
Common Stock, Par Value	$ 0.0001	$ 0.0001
Common Stock, Shares Authorized	100,000,000	100,000,000
Common Stock, Shares, Issued	420,621	420,621
Common Stock, Shares, Outstanding	420,621	420,621
Treasury Stock, Common, Shares		520,000

CONSOLIDATED STATEMENT OF OPERA

CONSOLIDATED STATEMENT OF OPERATIONS - USD ($)	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Operating Expenses:
Professional Fees	$ 56,548	$ 51,800
Amortization Expense	4,601	1,534
General and Administrative Expense	16,868	20,180
Officer Compensation		1
Total Expenses:	78,017	73,515
Net Operating and Comprehensive Loss	(78,017)	(73,515)
Other Income:
Royalty Income		100,000
Total Other Income		100,000
Other Expenses:
Impairment Expense		625,000
Royalty Fee		90,000
Total Other Expense		715,000
Net Other Expense:		(615,000)
Net and Comprehensive Loss	$ (78,017)	$ (688,515)
Weighted average Net Loss per share, basic and diluted	$ (0.10)	$ (0.87)
Weighted average number of common shares outstanding	751,142	787,183

CONSOLIDATED STATEMENTS OF DEFI

CONSOLIDATED STATEMENTS OF DEFICIT (EQUITY) - USD ($)	Total	Preferred Stock [Member]	Common Stock [Member]	Share Subscription Received [Member]	Unissued Common Stock [Member]	Treasury Stock, Common [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]
Balance, July 31, 2021 at Jul. 31, 2021	$ (24,843)		$ 94				$ 120,187,430	$ (120,212,367)
Beginning Balance, Shares at Jul. 31, 2021			940,621
Net Loss	(42,255)							(42,255)
Balance, July 31, 2022 at Oct. 31, 2021	(67,097)	$ 1	$ 94				120,187,430	(120,254,622)
Ending Balance, Shares at Oct. 31, 2021		1,000	940,621
Shares Issued	1	$ 1
Shares issued, Shares		1,000
Balance, July 31, 2021 at Jul. 31, 2021	(24,843)		$ 94				120,187,430	(120,212,367)
Beginning Balance, Shares at Jul. 31, 2021			940,621
Share Subscription Received
Net Loss	(688,515)
Balance, July 31, 2022 at Jul. 31, 2022	41,246	$ 1	$ 94		750,000	$ (52)	120,192,085	(120,900,882)
Ending Balance, Shares at Jul. 31, 2022		1,000	940,621			(520,000)
Balance, July 31, 2021 at Oct. 31, 2021	(67,097)	$ 1	$ 94				120,187,430	(120,254,622)
Beginning Balance, Shares at Oct. 31, 2021		1,000	940,621
Net Loss	(13,795)							(13,795)
Balance, July 31, 2022 at Jan. 31, 2022	(80,892)	$ 1	$ 94				120,187,430	(120,268,417)
Ending Balance, Shares at Jan. 31, 2022		1,000	940,621
Net Loss	(5,837)							(5,837)
Balance, July 31, 2022 at Apr. 30, 2022	(86,729)	$ 1	$ 94				120,187,430	(120,274,254)
Ending Balance, Shares at Apr. 30, 2022		1,000	940,621
Net Loss	(626,628)							(626,628)
Balance, July 31, 2022 at Jul. 31, 2022	41,246	$ 1	$ 94		750,000	$ (52)	120,192,085	(120,900,882)
Ending Balance, Shares at Jul. 31, 2022		1,000	940,621			(520,000)
Settlement (Note 6)	4,603					$ (52)	4,655
Settlement, Shares						(520,000)
Unissued Common Stock	750,000				750,000
Share Subscription Received	10,000			10,000
Net Loss	(28,071)							(28,071)
Balance, July 31, 2022 at Oct. 31, 2022	23,175	$ 1	$ 94	10,000	750,000	$ (52)	120,192,085	(120,928,953)
Ending Balance, Shares at Oct. 31, 2022		1,000	940,621			(520,000)
Balance, July 31, 2021 at Jul. 31, 2022	41,246	$ 1	$ 94		750,000	$ (52)	120,192,085	(120,900,882)
Beginning Balance, Shares at Jul. 31, 2022		1,000	940,621			(520,000)
Share Subscription Received	(20,000)
Net Loss	(78,017)
Balance, July 31, 2022 at Jul. 31, 2023	(16,771)	$ 1	$ 42	20,000	750,000		120,192,085	(120,978,899)
Ending Balance, Shares at Jul. 31, 2023		1,000	420,621
Balance, July 31, 2021 at Oct. 31, 2022	23,175	$ 1	$ 94	10,000	750,000	$ (52)	120,192,085	(120,928,953)
Beginning Balance, Shares at Oct. 31, 2022		1,000	940,621			(520,000)
Net Loss	(13,154)							(13,154)
Balance, July 31, 2022 at Jan. 31, 2023	20,021	$ 1	$ 94	20,000	750,000	$ (52)	120,192,085	(120,942,107)
Ending Balance, Shares at Jan. 31, 2023		1,000	940,621			(520,000)
Net Loss	(9,773)							(9,773)
Balance, July 31, 2022 at Apr. 30, 2023	10,248	$ 1	$ 42	20,000	750,000		120,192,085	(120,951,880)
Ending Balance, Shares at Apr. 30, 2023		1,000	420,621
Share Cancellation			$ (52)			$ 52
Share Cancellation, Shares			(520,000)			520,000
Net Loss	(27,019)							(27,019)
Balance, July 31, 2022 at Jul. 31, 2023	$ (16,771)	$ 1	$ 42	$ 20,000	$ 750,000		$ 120,192,085	$ (120,978,899)
Ending Balance, Shares at Jul. 31, 2023		1,000	420,621

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended	12 Months Ended
	Oct. 31, 2022	Jul. 31, 2023	Jul. 31, 2022
Cash Flows from Operating Activities:
Net Loss	$ (28,071)	$ (78,017)	$ (688,515)
Non Cash Expense:
Amortization		4,601	1,534
Impairment of License			625,000
Officer Compensation			1
Change in Working Capital Items:
Accounts payable and Accrued expenses		53,079	68,095
Prepaid expense		(2,363)	(2,917)
Net Cash Provided (Used) by Operating Activities		(22,700)	3,198
Cash Flows from Financing Activities:
Share Subscriptions Received	(10,000)	20,000
Net Cash Provided by Financing Activities		20,000
Change in cash for the period		(2,700)	3,198
Beginning Cash	$ 3,198	3,198
Ending Cash		498	3,198
Supplemental disclosures of cash flow - cash paid for :
Interest
Income Tax
Unpaid license fees to be paid in common shares			$ 750,000

COMPANY AND BACKGROUND

COMPANY AND BACKGROUND	12 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
COMPANY AND BACKGROUND	Note 1 COMPANY AND BACKGROUND Point of Care Nano-Technology, Inc. (the “Company”) was incorporated under the laws of the State of Nevada on June 10, 2010, under the name of “Alternative Energy and Environmental Solutions, Inc.” On August 28, 2014, the Company filed an amendment to its Articles of Incorporation changing the name of the Company to “Unique Growing Solutions, Inc.” On March 31, 2015, the Company filed an amendment to its Articles of Incorporation changing the name of the Company to “Point of Care Nano-Technology, Inc.” On February 26, 2015, our business model was related to using its license, under a certain license agreement (the “License Agreement”) from Lamina Equities Corporation, to first develop and then manufacture saliva-based medical diagnosis products. The Company was not successful and discontinued the majority of its operations by July 31, 2016. Beginning from August 2016, our plan, which it has since discontinued, was to provide business services and financing to emerging growth entities. On April 15, 2021, the Company accepted the resignations of Dr. Guirguis and Mr. El-Salhy, received a mutual release from both, and appointed Mr. Nicholas DeVito to be Director, Chief Executive Officer and Chief Financial Officer. In addition, for his services to the Company, Mr. DeVito was awarded 1,000 shares of Class A Preferred Stock that grants him 80% voting rights. Also on April 15, 2021 the Company agreed to form a subsidiary and transfer all debts and the License Agreement back to Dr. Guirguis in exchange for 520,000 shares of Common Stock. On August 231, 2021, the Company formed the wholly owned subsidiary, DRG Transfer, Inc. This transaction closed on March 26, 2022. On July 2, 2021, the Company incorporated a wholly owned subsidiary, Duo Sciences, Inc. (“DSI”). On April 11, 2022, the Company, through DSI, acquired an exclusive license to distribute certain intellectual property in animal nutrition and animal supplements from Cedoga Consulting, LLC (“Cedoga”). On April 19, 2022, DSI signed an exclusive sales and promotion agreement with Lucy Pet Products Inc. (“Lucy”) pursuant to which Lucy will manufacture, market and distribute pet products from the Cedoga intellectual property. U.S. patent application 16/930,604 was allowed on March 29, 2023, and will issue shortly, further strengthening our subsidiary, DSI, intellectual property position and coverage for its DUOS products. The allowed claims are directed to an edible pet chew that contains a thermo-processed shell having a cylindrical shape and that includes cellulosic fibers, a humectant, and a gelling agent, and within the shell is a cold-formed filler that contains a fat mimicking composition and a thermally labile active containing an enzyme. The pet chew provides oral care properties and contains thermal labile nutrients and/or actives whose nutrient values and activities are preserved. The pet chews provide salivatory stimulation when consumed by the pet, which in combination with the other ingredients of the pet chew provide dental care properties to remove dental plaque, stain, and tartar on a tooth surface, as well as protection of the oral and perioral tissues. A continuation patent application seeking to further protect the pet chew oral care technology was also filed. The application has been assigned serial number 18/133,381 and the filing date was April 11, 2023. On December 12, 2022, the Company entered into an asset purchase agreement with Global Foods Group, LLC (“GFG”) and its principal shareholder pursuant to which it agreed to acquire substantially all of the assets of GFG, consisting of assets relating to the sugar substitute that GFG has been developing, Jaca ® The Company’s July 31, 2022 financial statements have been restated to reflect changes to the valuation of the original Lucy Pet Products license. This original value is now based on the market prices of the shares at the time of the transaction and was impaired at year end 2022. In addition, corrections to the par value of our common stock are now reflected in the financial statements. See the Table below for the adjustments. Schedule of financial statements have been restated to reflect changes Account As Originally Filed As Restated Variance Explanation License 125,000.00 125,000.00 - Original purchase of license value was increased by $750,000; restatement includes write off of ($125,000) license fee payable and subsequent ($625,000) impairment License Fee Payable 125,000.00 - 125,000.00 Original purchase of license value was increased by $750,000; restatement includes write off of ($125,000) license fee payable and subsequent ($625,000) impairment License Impairment - 625,000.00 (625,000.00 ) Original purchase of license value was increased by $750,000; restatement includes write off of ($125,000) license fee payable and subsequent ($625,000) impairment Royalty Revenue 100,000.00 100,000.00 - Reclassification from Operating Income to Other Income Royalty Fees 90,000.00 90,000.00 - Reclassification from Operating Expense to Other Expense Common Stock to be issued - 750,000.00 (750,000.00 ) Common Stock due to be issued for increase in original purchase value of license of $750,000 Common Stock 940.00 94.00 846.00 Original par value was incorrect at .001/share; corrected at .0001/share Treasury Stock 520.00 52.00 468.00 Original par value was incorrect at .001/share; corrected at .0001/share The Company’s principal executive office location and mailing address is 109 Ambersweet Way, Davenport, FL 33897.

CONTROL BY PRINCIPAL OWNERS

CONTROL BY PRINCIPAL OWNERS	12 Months Ended
	Jul. 31, 2023
Control By Principal Owners
CONTROL BY PRINCIPAL OWNERS	Note 2 CONTROL BY PRINCIPAL OWNERS The directors and executive officers own, directly or indirectly, beneficially and in the aggregate, the majority of the voting power of the outstanding capital stock of the Company. Accordingly, directors, executive officers and their affiliates, if they voted their shares uniformly, would have the ability to control the approval of most corporate actions, including approving significant expenses, increasing the authorized capital and the dissolution, merger, or sale of our assets.

GOING CONCERN

GOING CONCERN	12 Months Ended
	Jul. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GOING CONCERN	Note 3 GOING CONCERN These financial statements have been prepared in accordance with generally accepted principles applicable to a going concern, which assumes that the Company will be able to meet its obligations and continue its operations for its next twelve months. Realization values may be substantially different from carrying values as shown and these financial statements do not give effect to adjustments that would be necessary to the carrying values and classifications of assets and liabilities should the Company be unable to continue as a going concern. At July 31, 2023, the Company had not yet achieved profitable operations and had accumulated losses of $ 120,978,899 498

ACCOUNTING POLICIES

ACCOUNTING POLICIES	12 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
ACCOUNTING POLICIES	Note 4 ACCOUNTING POLICIES The financial statements and accompanying notes are prepared in accordance with accounting principles generally accepted in the United States of America, the more significant of which are as follows: Consolidation The accompanying consolidated financial statement include the accounts of the Company and its wholly owned subsidiary Duo Sciences Inc. (“DSI”) Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available to management. Actual results could differ from those estimates. Financial Instruments Financial instruments consist of cash and accounts payable and accrued liabilities. The carrying amounts of the financial instruments approximate their fair values due to their relatively short-term nature of the underlying terms are consistent with market terms. As of the financial statement date, the Company does not hold any derivate financial instruments. Financial assets and liabilities are measured upon first recognition and reviewed at the financial statement date. Changes in fair value are recognized through profit and loss. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments. Fair Value Measurements The Company follows FASB Codification topic (“ASC”) 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk. The Company has adopted FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. The Company has not elected the fair value option for any eligible financial instruments. An asset or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities, and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities. Revenue Recognition Effective August 1, 2018, the Company adopted ASC, Topic 606, “Revenue from Contracts with Customers”, using the modified retrospective transition method as permissible for all contracts not yet completed as of August 1, 2018. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contracts) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. Income Taxes The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes (“ASC Topic 740”). Under ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As the Company has yet to produce positive cash flows from operations, no deferred tax asset or income taxes have been recorded in the financial statements. Comprehensive Income (Loss) The Company adopted FASB ASC 220, Reporting Comprehensive Income, which establishes standards for the reporting and display of comprehensive income and its components in the financial statements. Comprehensive income consists of net income and other gains and losses affecting stockholder’s equity that are excluded from net income, such as unrealized gains and losses on investments available for sale, foreign currency translation gains and losses and minimum pension liability. Since inception, the Company has not had any comprehensive income / loss. Net Income (Loss) per Common Share FASB ASC 260, Earnings per share, requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per share would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per share on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive. Accordingly, although the diluted weighted average number of common stock outstanding is disclosed on the statements of operation, the calculated net loss per share is the same for bother basic and diluted as both are based on the basic weighted average of common stock outstanding. There were no adjustments required to net income for the period presented in the computation of diluted earnings per share. Segment Reporting FASB ASC 820, “Segments Reporting,” establishes standards for reporting information about operating segments on a basis consistent with our internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. The Company currently operates in one principal business segment. Intangible assets Intangible asset are non-monetary identifiable assets, controlled by the Company that will produce future economic benefits, based on reasonable and supportable assumptions about conditions that will exist over the life of the asset. An intangible asset that does not meet these attributes will be recognized as an expense when it is incurred. Intangible assets that do, are capitalized and initially measure at cost. Those with a determinable life will be amortized on a systematic basis over their future economic life. Those with an indefinite useful life shall not be amortized until its useful life is determined to be longer than indefinite. An intangible asset subject to amortization shall be periodically reviewed for impairment. A recoverability test will be performed and, if applicable, unscheduled amortization is considered. The license agreements has been capitalized, recorded at cost and amortized over its estimated useful life of ten years. Amortization has been determined based on a pro rata basis over the expected cash flows. Non-cash transactions The Company follows FASB ASC 845 then recording non-cash transactions. The value of the asset received should be based on the value of the assets surrendered. However, where that value is difficult to determine, then the value could be based on the asset received, provided it is more clearly evident than the value of the asset surrendered. Related Parties The Company adopted FASB ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions. Recent Accounting Pronouncements The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position, or cash flow.

COMMON and PREFERRED STOCK

COMMON and PREFERRED STOCK	12 Months Ended
	Jul. 31, 2023
Equity [Abstract]
COMMON and PREFERRED STOCK	Note 5 COMMON and PREFERRED STOCK The Company has authorized capital of 100,000,000 0.0001 10,000,000 0.0001 On June 8, 2022, the Company received approval from the Financial Industry Regulatory Authority to effect a 50:1 reverse split of our outstanding common stock. The split was reflected in the public markets on June 9, 2022 and has been given retroactive disclosure in the financial statements. On August 2, 2021, the Company issued 1,000 Nicholas DeVito On April 10, 2022, the Company entered into an agreement under which it agreed to issue 300,000 common shares in order to obtain a license to distribute product (See below). The Company has not yet issued those shares and the obligation to do so is recorded as a $ 750,000 On April 15, 2022, as part of the Settlement agreement (See below), the Company received into treasury 520,000 On June 8, 2022, the Company received approval from the Financial Industry Regulatory Authority to effect a 50:1 reverse split of our outstanding common stock. The split was reflected in the public markets on June 9, 2022 and has been given retroactive disclosure in the financial statements. Accordingly, all references to common shares in these financial statements reflect the reverse split. On August 24, 2022, the Company completed a financing with an investor for $20,000 in exchange for Units consisting of (i) one share of common stock, par value $0.0001 per share for $0.10 per share, (ii) one LOI option to purchase one share of common stock for $0.20 per share upon the Company signing a letter of intent with a third party and (iii) one Agreement option to purchase one share of common stock for $0.30 per share upon the Company signing an agreement with a third party. There were no warrants or options outstanding as of July 31, 2023.

SETTLEMENT AGREEMENT

SETTLEMENT AGREEMENT	12 Months Ended
	Jul. 31, 2023
Settlement Agreement
SETTLEMENT AGREEMENT	Note 6 SETTLEMENT AGREEMENT On April 15, 2021, the Company formed a wholly owned subsidiary, DRG Transfer Inc. (“DRG”) and transferred all Company debts relating to the License Agreement business and the License Agreement to DRG to be split off to Dr. Guirguis in exchange for 520,000 shares (26,000,000 shares pre reverse split) of our common stock held by Dr. Guirguis. This transaction closed on March 26, 2022 with Dr. Guirguis giving up and transferring to DRG all the rights, title and interest in the 520,000 shares and DRG contributing all of the legacy business debt and the License Agreement to DRG Transfer, Inc, a Nevada corporation, and transferring all of the outstanding capital stock in DRG Transfer, Inc. to Dr. Guirguis Outstanding debts of the Company that were generated while Mr. Guirguis operated the Company, measured as of April 15, 2021, consisted solely of unknown contingent liabilities (which could be identified or quantified at that time and which, to date, have been non-material or nil.

LICENSE PURCHASED and INTANGIBL

LICENSE PURCHASED and INTANGIBLE ASSETS	12 Months Ended
	Jul. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
LICENSE PURCHASED and INTANGIBLE ASSETS	Note 7 LICENSE PURCHASED and INTANGIBLE ASSETS On April 11, 2022, the Company, through its wholly owned subsidiary DSI, acquired an exclusive license to distribute in the USA, Canada and Mexico, certain intellectual property in animal nutrition and animal supplements from Cedoga Consulting, LLC. The Company receives 10% of all licensing fees due to Cedoga in exchange for 300,000 post reverse split shares of common stock of the Company. Under the terms of the agreement, the Company will pay royalties from sub-licensing on the following basis: ● 90% of net royalties for sale and initial payments up to $100,000,000 per calendar year. ● 95% of net royalties received for continuing sales above $100,000,000 per calendar year. ● 90% of any lump up-front payment sub-licensing fees. ● Option to purchase 200,000 shares of our common stock when net sales exceed $100,000,000. The license value has been based on the value of the common shares at the time of the transaction and originally valued at $750,000. After further financial projection analysis we recorded an impairment of $625,000 reducing the total value of the license to $125,000. Schedule of License Purchased As of July 31 2023 2022 License $ 125,000 $ 125,000 Accumulated amortization 6,135 1,534 Balance, end of year $ 118,865 $ 123,466

EXCLUSIVE SALES SUB-LICENSING A

EXCLUSIVE SALES SUB-LICENSING AGREEMENT	12 Months Ended
	Jul. 31, 2023
Exclusive Sales Sub-licensing Agreement
EXCLUSIVE SALES SUB-LICENSING AGREEMENT	Note 8 EXCLUSIVE SALES SUB-LICENSING AGREEMENT On April 19, 2022, DSI signed an exclusive sales and promotion sub-licensing agreement with Lucy Pet Products Inc. (“Lucy”) pursuant to which Lucy will manufacture, market and distribute pet products derived from the Cedoga intellectual property. The terms of the sub-licensing agreement are as follows: ● Lucy will pay the Company a one-time sub-license fee of $100,000 on execution of the sub-licensing agreement. ● Lucy will pay the Company royalties of 5% of Net Revenue, calculated and payable quarterly. Net Revenue is defined as total revenue less direct cost of materials, manufacturing, packaging and delivery expenses and less excise, sales or similar taxes. On May 11, 2022, the Company received the first payment from Lucy of $ 100,000 90,000

INCOME TAXES

INCOME TAXES	12 Months Ended
	Jul. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	Note 9 INCOME TAXES As at July 31, 2023, no tax benefit has been recorded with respect to the net operating loss in the financial statements as the management of the Company believes that the realization of our net deferred tax assets would not be considered more likely than not and accordingly, the potential tax benefits of the net loss carry-forwards are offset by the full valuation allowance. The Company has a net operating loss carryforward of approximately $ 1,813,968 Income tax recovery differs from that which would be expected from applying the effective tax rates to the net loss for the years ended July 31, 2023 and 2022 as follows: Schedule of Income tax Reconciliation Year Ended July 31 2023 2022 Net loss for the year $ (78,017 ) $ (688,515 ) Statutory and effective tax rate 25.46 % 25.46 % Expected income tax recovery $ (19,863 ) $ (688,515 ) Tax benefit deferred 19,863 175,295 Income taxes recorded $ - $ - Schedule of Deferred Tax Assets Year Ended July 31 2023 2022 Tax losses carried forward $ 1,814,000 $ 1,814,000 Statutory and effective tax rate 25.46 % 25.46 % Deferred tax asset $ 462,000 $ 462,000 Valuation allowance (462,000 ) (462,000 ) Net deferred tax asset $ - $ - Our income tax filings are subject to audit by various taxing authorities. Our open audit periods include from Inception (June 10, 2010) to the current tax year.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	12 Months Ended
	Jul. 31, 2023
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	Note 10 SUBSEQUENT EVENTS On May 20, 2024, Point of Care Nano-Technology, Inc. (the “Company”) entered into an asset purchase agreement (the “Agreement”) with Point of Care Nano-Technology, LLC (“Point”) pursuant to which it agreed to acquire (the “Acquisition”) substantially all of the assets of Point (the “Assets”), consisting primarily of proprietary information and know-how for the developing and commercialization of kits to diagnose illnesses through the testing of human saliva, referred to as the “EZ Saliva” test kits, and cash in the amount of $101,400. In exchange for the Assets, the Company issued to Point and/or its designees 66,000,000 restricted shares of common stock (the “Consideration Shares”). Upon the closing of the Acquisition, which effected a change of control of the Company, Dr. Raouf Guirguis, the controlling member of Point, became a director of the Company and Chief Scientific Officer. Dr. Guirguis also acquired, directly and indirectly, 34,647,800 of the Consideration Shares, or approximately 47.6% of the shares of common stock outstanding after completion of the Acquisition. Mr. Nathan Keele, an associate of Dr. Guirguis and responsible for marketing efforts at Point, also was appointed to the board of directors of the Company. Mr. Keele will continue his marketing efforts at the Company. Mr. Keele acquired 18,903,200 of the Consideration Shares, or approximately 26.5% of the shares of common stock outstanding after completion of the Acquisition. Nicholas DeVito, the controlling stockholder of the Company prior to the Acquisition through the 1,000 shares of super-majority class A preferred stock (the “Preferred Stock”) of the Company that he held and through which he exercised eighty percent (80%) voting control over the Company, surrendered to the Company for cancellation the Preferred Stock and received, in exchange, 5,000,000 shares of common stock. Mr. DeVito will retain his positions as Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary of the Company as well as his status as a member of board of directors. The shares of Company common stock being issued in connection with the Acquisition (as described above) were issued in accordance with a private placement exemption from registration under Section 4(a)(2) of the Securities Act of 1933, as amended, and are considered “restricted securities.” In connection with the Acquisition, the Company entered into a license agreement (the “License Agreement”) with Zeus Diagnostics, LLC (“Zeus”), a Delaware limited liability company controlled by Dr. Guirguis, pursuant to which the Company acquired an exclusive, in perpetuity, license, with a right to sublicense, in the Territory (Canada, the United States and Mexico) to the “Zeus Know-How” which consists of all information related to the manufacture and commercialization of saliva tests derived from patents owned by Zeus. The Company paid Zeus a one-time, non-refundable up-front cash fee of $35,000 (which is creditable against other payments due) and will pay Zeus a royalty on “Net Sales” (as defined in the License Agreement) of Seven and One-Half Percent (7.5%) during each calendar quarter. Following the closing of the Acquisition, business will focus on the EZ Saliva product commercialization activity previously carried on by Point. On October 2, 2024 the Company issued 1,270,000 30,000 The description of the agreement discussed above does not purport to be complete and the reader should refer to the full text of the agreements attached hereto as exhibits.

ACCOUNTING POLICIES (Policies)

ACCOUNTING POLICIES (Policies)	12 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
Consolidation	Consolidation The accompanying consolidated financial statement include the accounts of the Company and its wholly owned subsidiary Duo Sciences Inc. (“DSI”)
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of financial statements and the reported amounts of revenues and expenses during the reporting period. Changes in estimates are recognized in accordance with the accounting rules for the estimate, which is typically in the period when new information becomes available to management. Actual results could differ from those estimates.
Financial Instruments	Financial Instruments Financial instruments consist of cash and accounts payable and accrued liabilities. The carrying amounts of the financial instruments approximate their fair values due to their relatively short-term nature of the underlying terms are consistent with market terms. As of the financial statement date, the Company does not hold any derivate financial instruments. Financial assets and liabilities are measured upon first recognition and reviewed at the financial statement date. Changes in fair value are recognized through profit and loss. Unless otherwise noted, it is management’s opinion that the Company is not exposed to significant interest or credit risks arising from these financial instruments.
Fair Value Measurements	Fair Value Measurements The Company follows FASB Codification topic (“ASC”) 820, Fair Value Measurements and Disclosures, for all financial instruments and non-financial instruments accounted for at fair value on a recurring basis. This new accounting standard establishes a single definition of fair value and a framework for measuring fair value, sets out a fair value hierarchy to be used to classify the source of information used in fair value measurement and expands disclosures about fair value measurements required under other accounting pronouncements. It does not change existing guidance as to whether or not an instrument is carried at fair value. The Company defines fair value as the price that would be received from selling an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities, which are required to be recorded at fair value, the Company considers the principal or most advantageous market in which the Company would transact and the market-based risk measurements or assumptions that market participants would use in pricing the asset or liability, such as inherent risk, transfer restrictions and credit risk. The Company has adopted FASB ASC 825, Financial Instruments, which allows companies to choose to measure eligible financial instruments and certain other items at fair value that are not required to be measured at fair value. The Company has not elected the fair value option for any eligible financial instruments. An asset or liability’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. Availability of observable inputs can vary and is affected by a variety of factors. The Company uses judgment in determining fair value of assets and liabilities, and Level 3 assets and liabilities involve greater judgment than Level 1 and Level 2 assets or liabilities.
Revenue Recognition	Revenue Recognition Effective August 1, 2018, the Company adopted ASC, Topic 606, “Revenue from Contracts with Customers”, using the modified retrospective transition method as permissible for all contracts not yet completed as of August 1, 2018. This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration that the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contracts) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer.
Income Taxes	Income Taxes The Company accounts for income taxes under FASB ASC Topic 740, Income Taxes (“ASC Topic 740”). Under ASC Topic 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Under ASC 740-10-25, the effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. Valuation allowances are established, when necessary, to reduce deferred tax assets to the amount expected to be realized. As the Company has yet to produce positive cash flows from operations, no deferred tax asset or income taxes have been recorded in the financial statements.
Comprehensive Income (Loss)	Comprehensive Income (Loss) The Company adopted FASB ASC 220, Reporting Comprehensive Income, which establishes standards for the reporting and display of comprehensive income and its components in the financial statements. Comprehensive income consists of net income and other gains and losses affecting stockholder’s equity that are excluded from net income, such as unrealized gains and losses on investments available for sale, foreign currency translation gains and losses and minimum pension liability. Since inception, the Company has not had any comprehensive income / loss.
Net Income (Loss) per Common Share	Net Income (Loss) per Common Share FASB ASC 260, Earnings per share, requires dual presentation of basic and diluted earnings per share (EPS) with a reconciliation of the numerator and denominator of the EPS computations. Basic earnings per share amounts are based on the weighted average shares of common stock outstanding. If applicable, diluted earnings per share would assume the conversion, exercise or issuance of all potential common stock instruments such as options, warrants and convertible securities, unless the effect is to reduce a loss or increase earnings per share. Diluted net income (loss) per share on the potential exercise of the equity-based financial instruments is not presented where anti-dilutive. Accordingly, although the diluted weighted average number of common stock outstanding is disclosed on the statements of operation, the calculated net loss per share is the same for bother basic and diluted as both are based on the basic weighted average of common stock outstanding. There were no adjustments required to net income for the period presented in the computation of diluted earnings per share.
Segment Reporting	Segment Reporting FASB ASC 820, “Segments Reporting,” establishes standards for reporting information about operating segments on a basis consistent with our internal organization structure as well as information about geographical areas, business segments and major customers in financial statements. The Company currently operates in one principal business segment.
Intangible assets	Intangible assets Intangible asset are non-monetary identifiable assets, controlled by the Company that will produce future economic benefits, based on reasonable and supportable assumptions about conditions that will exist over the life of the asset. An intangible asset that does not meet these attributes will be recognized as an expense when it is incurred. Intangible assets that do, are capitalized and initially measure at cost. Those with a determinable life will be amortized on a systematic basis over their future economic life. Those with an indefinite useful life shall not be amortized until its useful life is determined to be longer than indefinite. An intangible asset subject to amortization shall be periodically reviewed for impairment. A recoverability test will be performed and, if applicable, unscheduled amortization is considered. The license agreements has been capitalized, recorded at cost and amortized over its estimated useful life of ten years. Amortization has been determined based on a pro rata basis over the expected cash flows.
Non-cash transactions	Non-cash transactions The Company follows FASB ASC 845 then recording non-cash transactions. The value of the asset received should be based on the value of the assets surrendered. However, where that value is difficult to determine, then the value could be based on the asset received, provided it is more clearly evident than the value of the asset surrendered.
Related Parties	Related Parties The Company adopted FASB ASC 850, Related Party Disclosures, for the identification of related parties and disclosure of related party transactions.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company adopts new pronouncements relating to generally accepted accounting principles applicable to the Company as they are issued, which may be in advance of their effective date. The Company does not expect the adoption of recently issued accounting pronouncements to have a significant impact on our results of operations, financial position, or cash flow.

COMPANY AND BACKGROUND (Tables)

COMPANY AND BACKGROUND (Tables)	12 Months Ended
	Jul. 31, 2023
Accounting Policies [Abstract]
Schedule of financial statements have been restated to reflect changes	The Company’s July 31, 2022 financial statements have been restated to reflect changes to the valuation of the original Lucy Pet Products license. This original value is now based on the market prices of the shares at the time of the transaction and was impaired at year end 2022. In addition, corrections to the par value of our common stock are now reflected in the financial statements. See the Table below for the adjustments. Schedule of financial statements have been restated to reflect changes Account As Originally Filed As Restated Variance Explanation License 125,000.00 125,000.00 - Original purchase of license value was increased by $750,000; restatement includes write off of ($125,000) license fee payable and subsequent ($625,000) impairment License Fee Payable 125,000.00 - 125,000.00 Original purchase of license value was increased by $750,000; restatement includes write off of ($125,000) license fee payable and subsequent ($625,000) impairment License Impairment - 625,000.00 (625,000.00 ) Original purchase of license value was increased by $750,000; restatement includes write off of ($125,000) license fee payable and subsequent ($625,000) impairment Royalty Revenue 100,000.00 100,000.00 - Reclassification from Operating Income to Other Income Royalty Fees 90,000.00 90,000.00 - Reclassification from Operating Expense to Other Expense Common Stock to be issued - 750,000.00 (750,000.00 ) Common Stock due to be issued for increase in original purchase value of license of $750,000 Common Stock 940.00 94.00 846.00 Original par value was incorrect at .001/share; corrected at .0001/share Treasury Stock 520.00 52.00 468.00 Original par value was incorrect at .001/share; corrected at .0001/share

LICENSE PURCHASED and INTANGI_2

LICENSE PURCHASED and INTANGIBLE ASSETS (Tables)	12 Months Ended
	Jul. 31, 2023
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of License Purchased	Schedule of License Purchased As of July 31 2023 2022 License $ 125,000 $ 125,000 Accumulated amortization 6,135 1,534 Balance, end of year $ 118,865 $ 123,466

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Jul. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Income tax Reconciliation	Income tax recovery differs from that which would be expected from applying the effective tax rates to the net loss for the years ended July 31, 2023 and 2022 as follows: Schedule of Income tax Reconciliation Year Ended July 31 2023 2022 Net loss for the year $ (78,017 ) $ (688,515 ) Statutory and effective tax rate 25.46 % 25.46 % Expected income tax recovery $ (19,863 ) $ (688,515 ) Tax benefit deferred 19,863 175,295 Income taxes recorded $ - $ -
Schedule of Deferred Tax Assets	Schedule of Deferred Tax Assets Year Ended July 31 2023 2022 Tax losses carried forward $ 1,814,000 $ 1,814,000 Statutory and effective tax rate 25.46 % 25.46 % Deferred tax asset $ 462,000 $ 462,000 Valuation allowance (462,000 ) (462,000 ) Net deferred tax asset $ - $ -

COMPANY AND BACKGROUND (Details

COMPANY AND BACKGROUND (Details) - USD ($)	Jul. 31, 2023	May 31, 2023	Jul. 31, 2022
Common Stock	$ 42		$ 94
Treasury Stock			$ 52
Previously Reported [Member]
License		$ 125,000
License Fee Payable		125,000
License Impairment
Royalty Revenue		100,000
Royalty Fees		90,000
Common Stock to be issued
Common Stock		940
Treasury Stock		520
Revision of Prior Period, Adjustment [Member]
License		125,000
License Fee Payable
License Impairment		625,000
Royalty Revenue		100,000
Royalty Fees		90,000
Common Stock to be issued		750,000
Common Stock		94
Treasury Stock		52
Variance [Member]
License
License Fee Payable		125,000
License Impairment		(625,000)
Royalty Revenue
Royalty Fees
Common Stock to be issued		(750,000)
Common Stock		846
Treasury Stock		$ 468

GOING CONCERN (Details Narrativ

GOING CONCERN (Details Narrative) - USD ($)	Jul. 31, 2023	Jul. 31, 2022
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Retained Earnings (Accumulated Deficit)	$ 120,978,899	$ 120,900,882
Cash Equivalents, at Carrying Value	$ 498	$ 3,198

COMMON and PREFERRED STOCK (Det

COMMON and PREFERRED STOCK (Details Narrative) - USD ($)		12 Months Ended
	Jun. 08, 2022	Jul. 31, 2023	Jul. 31, 2022	Apr. 15, 2022	Aug. 02, 2021
Equity [Abstract]
Common Stock, Shares Authorized		100,000,000	100,000,000
Common Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Preferred Stock, Shares Authorized		10,000,000	10,000,000
Preferred Stock, Par or Stated Value Per Share		$ 0.0001	$ 0.0001
Stockholders' Equity, Reverse Stock Split	On June 8, 2022, the Company received approval from the Financial Industry Regulatory Authority to effect a 50:1 reverse split of our outstanding common stock. The split was reflected in the public markets on June 9, 2022 and has been given retroactive disclosure in the financial statements.
Preferred Stock, Shares Issued		1,000	1,000		1,000
[custom:LicenseFeeToBePaidInCommonShares]			$ 750,000
[custom:TreasuryStockShares1-0]				520,000

LICENSE PURCHASED and INTANGI_3

LICENSE PURCHASED and INTANGIBLE ASSETS (Details) - USD ($)	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Goodwill and Intangible Assets Disclosure [Abstract]
License	$ 125,000	$ 125,000
Accumulated amortization	6,135	1,534
Balance, end of year	$ 118,865	$ 123,466

EXCLUSIVE SALES SUB-LICENSING_2

EXCLUSIVE SALES SUB-LICENSING AGREEMENT (Details Narrative) - USD ($)		12 Months Ended
	May 11, 2022	Jul. 31, 2023	Jul. 31, 2022
Exclusive Sales Sub-licensing Agreement
Revenues, Excluding Interest and Dividends	$ 100,000
Royalty Expense	$ 90,000		$ 90,000

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	3 Months Ended								12 Months Ended
	Jul. 31, 2023	Apr. 30, 2023	Jan. 31, 2023	Oct. 31, 2022	Jul. 31, 2022	Apr. 30, 2022	Jan. 31, 2022	Oct. 31, 2021	Jul. 31, 2023	Jul. 31, 2022
Income Tax Disclosure [Abstract]
Net loss for the year	$ (27,019)	$ (9,773)	$ (13,154)	$ (28,071)	$ (626,628)	$ (5,837)	$ (13,795)	$ (42,255)	$ (78,017)	$ (688,515)
Statutory and effective tax rate									25.46%	25.46%
Expected income tax recovery									$ (19,863)	$ (688,515)
Tax benefit deferred									19,863	175,295
Income taxes recorded

INCOME TAXES (Details 2)

INCOME TAXES (Details 2) - USD ($)	12 Months Ended
	Jul. 31, 2023	Jul. 31, 2022
Income Tax Disclosure [Abstract]
Tax losses carried forward	$ 1,814,000	$ 1,814,000
Statutory and effective tax rate	25.46%	25.46%
Deferred tax asset	$ 462,000	$ 462,000
Valuation allowance	(462,000)	(462,000)
Net deferred tax asset

INCOME TAXES (Details Narrative

INCOME TAXES (Details Narrative)	Jul. 31, 2023 USD ($)
Income Tax Disclosure [Abstract]
Operating Loss Carryforwards	$ 1,813,968

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative) - USD ($)		3 Months Ended
	Oct. 02, 2024	Oct. 31, 2021
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues		$ 1
Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Value, New Issues	$ 30,000
Subsequent Event [Member] | Common Stock [Member]
Subsequent Event [Line Items]
Stock Issued During Period, Shares, New Issues	1,270,000